COMMUNITY study

The COMMUNITY pandemic surveillance cohort is a longitudinal cohort study including 2149 healthcare workers and 118 COVID-19 patients. Dataset includes: 1. Serological data at baseline April-May 2020 and at follow-up every four month (ongoing). 2. Data on memory T cell responses  3. Register data from Swedish vaccination register (VAL Vaccinera) and national communicable diseases register SmiNet (Public Health Agency of Sweden). 3. Self-reported symptoms compatible with COVID-19 since 1 January 2020, occupation, work location and exposure to patients infected with SARS-CoV-2 prior to blood sampling (healthcare workers). 3. Clinical data including co-morbidities, disease severity, on-going medications, demography (COVID-19 patients). Abstract The COMMUNITY pandemic surveillance cohort was initiated in April 2020 and comprises 2149 healthcare workers and 118 COVID-19 patients. Blood samples are collected every four months. Serological and cellular immune responses are continuously mapped to demography, vaccination(s) and prior infection. qPCR screening programs, including viral sequencing and culturing, are conducted during time points with high viral transmission and in response to the threat of emerging variants of concern (VOC).  The COMMUNITY pandemic surveillance cohort is conducted through close collaborations within the SciLifeLab community, the Public Health Agency of Sweden and the Swedish Armed Forces.  Publications Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. (http://www.ncbi.nlm.nih.gov/pubmed/35444806Opens in a new tab) Havervall S, Marking U, Greilert-Norin N et al. Clinical & Translational Immunology 2022;11(4):e1388. https://doi.org/10.1002/cti2.1388Opens in a new tab Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. (http://www.ncbi.nlm.nih.gov/pubmed/35334989Opens in a new tab) Marking U, Havervall S, Greilert-Norin N, et al.  Vaccines 2022;10(3). https://doi.org/10.3390/vaccines10030359Opens in a new tab A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies. (http://www.ncbi.nlm.nih.gov/pubmed/34628049Opens in a new tab) Mravinacova S, Jönsson M, Christ W, Klingström J . et al.  New biotechnology 2022;66():46-52. https://doi.org/10.1016/j.nbt.2021.10.002Opens in a new tab Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. (http://www.ncbi.nlm.nih.gov/pubmed/35349756Opens in a new tab) Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin et al. Immunity, inflammation and disease 2022;10(4):e595. https://doi.org/10.1002/iid3.595Opens in a new tab Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al. (http://www.ncbi.nlm.nih.gov/pubmed/34731533Opens in a new tab) Von Meijenfeldt Fa, Havervall S, Adelmeijer J, Thalin C, Lisman T JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2022;20(1):267-269. https://doi.org/10.1111/jth.15580Opens in a new tab Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. (http://www.ncbi.nlm.nih.gov/pubmed/34459525Opens in a new tab) Havervall S, Ng H, Falk Aj, Greilert-Norin et al. JOURNAL OF INTERNAL MEDICINE 2022;291(1):72-80. https://doi.org/10.1111/joim.13387Opens in a new tab SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection (http://www.ncbi.nlm.nih.gov/pubmed/35020778Opens in a new tab) . Havervall S, Jernbom Falk A, Klingström J et al.. PloS one 2022;17(1):e0262169. https://doi.org/10.1371/journal.pone.0262169Opens in a new tab A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation (http://www.ncbi.nlm.nih.gov/pubmed/35141170Opens in a new tab) . Heber S, Pereyra D, Schrottmaier Wc et al.Assinger A Frontiers in cellular and infection microbiology 2021;11():795026. https://doi.org/10.3389/fcimb.2021.795026Opens in a new tab An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. Mangsbo Sm, Havervall S, Laurén I et al. PloS one. 2021;16(9):e0258041. https/doi.org/10.1371/journal.pone.0258041 (https://doi.org/10.1371/journal.pone.0258041Opens in a new tab) Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 (http://www.ncbi.nlm.nih.gov/pubmed/34391088Opens in a new tab) . Havervall S, Marking U, Greilert-Norin N, Ng H, Gordon M, Salomonsson Ac, Hellström C, Pin E, Blom K, Mangsbo S, Phillipson M, Klingström J, Hober S, Nilsson P, Åberg M, Thålin C. EBioMedicine 2021;70():103523. htttps//doi.org/10.1016/j.ebiom.2021.103523 (https://doi.org/10.1016/j.ebiom.2021.103523Opens in a new tab) Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19. (http://www.ncbi.nlm.nih.gov/pubmed/33267662Opens in a new tab) Ng H, Havervall S, Rosell A, Aguilera K, Parv K, Von Meijenfeldt Fa, Lisman T, Mackman N, Thålin C, Phillipson M. Arteriosclerosis, Thrombosis, and Vascular Biology 2021;41(2):988-994. https/doi.org/10.1161/ATVBAHA.120.315267 (https://doi.org/10.1161/atvbaha.120.315267Opens in a new tab) COVID-19 is Associated with an Acquired Factor XIII Deficiency. (http://www.ncbi.nlm.nih.gov/pubmed/33742434Opens in a new tab) Von Meijenfeldt Fa, Havervall S, Adelmeijer J, Lundström A, Magnusson M, Mackman N, Thalin C, Lisman T. Thrombosis and Haemostasis 2021;121(12):1668-1669. https://doi.orgOpens in a new tab 10.1055/a-1450-8414 (https://doi.org/10.1055/a-1450-8414Opens in a new tab) Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality. (http://www.ncbi.nlm.nih.gov/pubmed/33393103Opens in a new tab) Von Meijenfeldt Fa, Havervall S, Adelmeijer J, Lundström A, et al. American Journal of Hematology 2021;96(4):E98-E100. https://doi.org/10.1002/ajh.26085Opens in a new tab Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report (http://www.ncbi.nlm.nih.gov/pubmed/33267656Opens in a new tab) Rosell A, Havervall S, Von Meijenfeldt F, et al. Arteriosclerosis, thrombosis, and vascular biology 2021;41(2):878-882 . https://doi.org/10.1002/rth2.12462Opens in a new tab Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality (http://www.ncbi.nlm.nih.gov/pubmed/33537537Opens in a new tab) Von Meijenfeldt Fa, Havervall S, Adelmeijer J et al. Research and practice in thrombosis and haemostasis 2021;5(1):132-141 Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers (http://www.ncbi.nlm.nih.gov/pubmed/34138483Opens in a new tab) Lundström A, Ziegler L, Havervall S. et al. Journal of Medical Virology 2021;93(10):5908-5916 Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. (http://www.ncbi.nlm.nih.gov/pubmed/33560386Opens in a new tab) Von Meijenfeldt Fa, Havervall S, Adelmeijer J, et al.  Blood Advances 2021;5(3):756-759. https://doi.org/10.1182/bloodadvances.2020003968Opens in a new tab  Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers (http://www.ncbi.nlm.nih.gov/pubmed/33825846Opens in a new tab) Havervall et al. JAMA 2021;325(19):2015-2016. https://doi.org/10.1001/jama.2021.5612Opens in a new tab Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay. (http://www.ncbi.nlm.nih.gov/pubmed/34295471Opens in a new tab) Hober S, Hellstrom C, Olofsson J et al. CLINICAL & TRANSLATIONAL IMMUNOLOGY 2021;10(7):e1312.   https://doi.org/10.1002/cti2.1312Opens in a new tab SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. (http://www.ncbi.nlm.nih.gov/pubmed/33033249Opens in a new tab) Rudberg As, Havervall S, Månberg A, Jernbom Falk A, et al. C. Nature Communications 2020;11(1):5064 https:/doi.org/10.1038/s41467-020-18848-0 (https://doi.org/10.1038/s41467-020-18848-0Opens in a new tab)